CDER Attacks Genentech's Plans For New Confirmatory Trial At Avastin Hearing

Proposed study of bevacizumab in first-line metastatic breast cancer is unlikely to substantiate the magnitude of progression-free survival benefit seen in the E2100 trial, Division of Biologic Oncology Products Director Patricia Keegan says.